Literature DB >> 8582465

Pharmacological effects of concomitant administration of beta-adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of beta-blocker combined with beta-agonist.

M Karita1, H Sato, Y Koretsune, K Imai, H Ozaki, H Yokoyama, M Hori, H Takeda, M Inoue, T Kamada.   

Abstract

The effects of a combination regimen of metoprolol and beta 1-adrenoceptor agonist denopamine on resting and exercise heart rate have been studied in 10 normal volunteers. Maximal ramp upright bicycle exercise was performed three times at 1-week intervals. Two hours before each exercise test, 5 mg metoprolol plus 20 mg denopamine, 5 mg metoprolol plus a denopamine placebo, or two placebos were orally administered in a double-blind fashion. During exercise after placebo administration, heart rate increased in parallel with the exercise intensity. Compared to the placebo values, resting heart rate was significantly decreased by an average of 10 beats.min-1 by 5 mg metoprolol, whereas it was not altered by the combination regimen. During exercise, however, both the combination regimen and metoprolol alone showed a significant negative chronotropic effect, decreasing peak exercise heart rate by an average of 14 and 21 beats.min-1, respectively. Peak oxygen uptake was also significantly decreased by both regimens. We conclude that concomitant administration of 5 mg metoprolol and 20 mg denopamine exerts an effective beta-adrenoceptor blocking action during exercise but a minimal effect at rest in normal subjects. The combination regimen appears to have a favourable pharmacological profile for beta-adrenoceptor blocker therapy in patients with chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582465     DOI: 10.1007/bf00194336

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.

Authors:  D G Waller; J Webster; C A Sykes; K K Bhalla; R Wray
Journal:  Eur Heart J       Date:  1989-11       Impact factor: 29.983

2.  Effects of cardioselective and nonselective beta-blockade on dynamic exercise performance in mildly hypertensive men.

Authors:  F H Leenen; C H Coenen; M Zonderland; A H Maas
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

3.  Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.

Authors:  H Sato; M Inoue; T Matsuyama; H Ozaki; T Shimazu; H Takeda; Y Ishida; T Kamada
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

4.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.

Authors:  S L Woodley; E M Gilbert; J L Anderson; J B O'Connell; D Deitchman; F G Yanowitz; P C Mealey; K Volkman; D G Renlund; R Menlove
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

5.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure.

Authors:  B Andersson; C Blomström-Lundqvist; T Hedner; F Waagstein
Journal:  J Am Coll Cardiol       Date:  1991-10       Impact factor: 24.094

6.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

7.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.

Authors:  S M Heilbrunn; P Shah; M R Bristow; H A Valantine; R Ginsburg; M B Fowler
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

8.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

9.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.

Authors:  R S Engelmeier; J B O'Connell; R Walsh; N Rad; P J Scanlon; R M Gunnar
Journal:  Circulation       Date:  1985-09       Impact factor: 29.690

10.  Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.

Authors:  H Pouleur; J Etienne; H Van Mechelen; O Gurné; M F Rousseau
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.